期刊
JOURNAL OF IMMUNOLOGY
卷 205, 期 10, 页码 2640-2648出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1900883
关键词
-
类别
资金
- CSL Behring [RS 01/2009]
- Swiss National Science Foundation [310030_184757, 310030_162552, 310030_135734, 323530-139174, 310030_184816]
- Bulgarian-Swiss Research Program [IZEBZO_142967]
- Bern Center for Precision Medicine
- European Union Horizon 2020 Research and Innovation Program (Marie Sklodowska-Curie Grant) [642295]
- Swiss National Science Foundation (SNF) [310030_135734, 310030_184757, 323530-139174, 310030_162552] Funding Source: Swiss National Science Foundation (SNF)
IVIG preparations consisting of pooled IgG are increasingly used for the treatment of autoimmune diseases. IVIG is known to regulate the viability of immune cells, including neutrophils. We report that plasma-derived IgA efficiently triggers death of neutrophils primed by cytokines or TLR agonists. IgA-mediated programmed neutrophil death was PI3K-, p38 MAPK-, and JNK-dependent and evoked anti-inflammatory cytokines in macrophage cocultures. Neutrophils from patients with acute Crohn's disease, rheumatoid arthritis, or sepsis were susceptible to both IgA- and IVIG-mediated death. In contrast to IVIG, IgA did not promote cell death of quiescent neutrophils. Our findings suggest that plasma-derived IgA might provide a therapeutic option for the treatment of neutrophil-associated inflammatory disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据